FB-825
- Generic Name
- FB-825
- Drug Type
- Biotech
- Unique Ingredient Identifier
- YO4XL7781V
- Background
FB-825 is an investigational humanized monoclonal antibody that targets the CεmX domain of the membrane-bound IgE (mIgE), causing a depletion of mIgE positive B-cells. It is currently being investigated for immune disorders, such as atopic dermatitis and hyperimmunoglobulin E syndrome (HIES).
Robust Pipeline of 50+ Therapies Reshaping Moderate to Severe Atopic Dermatitis Treatment Landscape
• The moderate to severe atopic dermatitis market is experiencing significant growth with 45+ companies developing over 50 pipeline therapies, driven by rising global prevalence and increased awareness of the condition.
• Recent advancements include promising biologics like rezpegaldesleukin (granted FDA fast-track designation), JAK inhibitors such as VC005 and QY201, and novel mechanisms targeting IL-4/IL-13 pathways, offering new hope for patients with inadequate response to current treatments.
• Key players including Nektar Therapeutics, Corvus Pharmaceuticals, and Apogee Therapeutics are advancing clinical trials with significant milestones expected in late 2025, potentially transforming the therapeutic landscape for this chronic inflammatory skin condition.
Breakthrough siRNA Drug SNS812 for COVID-19 Selected for Prestigious ATS 2025 Presentation
• Oneness Biotech and Microbio Shanghai's SNS812, the world's first fully modified siRNA drug administered via aerosol inhalation, has been selected for oral presentation at the 2025 ATS International Conference.
• Phase II clinical trial results demonstrate SNS812 significantly reduces SARS-CoV-2 viral load, accelerates symptom resolution, and shortens recovery time for smell and taste loss, with excellent safety profile.
• The selection for the conference's highest-tier Mini Symposium format validates the companies' technological platform in nucleic acid drug development and their innovative approach to precision antiviral therapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath